Education
About Us
Working with TipRanks
Follow Us
Prophase Labs (PRPH)
NASDAQ:PRPH
PRPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $3.00
Previous CloseN/A
Volume469.10K
Average Volume (3M)10.47M
Market Cap
$13.81M
Enterprise Value$23.95M
Total Cash (Recent Filing)$171.00K
Total Debt (Recent Filing)$5.54M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 06, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 24, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding41,541,206
10 Day Avg. Volume29,435,747
30 Day Avg. Volume10,469,718
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.73
Enterprise Value/Revenue7.17
Enterprise Value/Gross Profit11.86
Enterprise Value/Ebitda-0.91
Forecast
1Y Price Target
$0.50Price Target Upside42.86% Upside
Rating ConsensusHold
Number of Analyst Covering1
Prophase Labs News
PRPH FAQ
What was Prophase Labs’s price range in the past 12 months?
Prophase Labs lowest stock price was $0.22 and its highest was $3.00 in the past 12 months.
What is Prophase Labs’s market cap?
Prophase Labs’s market cap is $13.81M.
When is Prophase Labs’s upcoming earnings report date?
Prophase Labs’s upcoming earnings report date is Nov 06, 2025 which is in 82 days.
How were Prophase Labs’s earnings last quarter?
Prophase Labs released its earnings results on Aug 13, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.04.
Is Prophase Labs overvalued?
According to Wall Street analysts Prophase Labs’s price is currently Undervalued.
Does Prophase Labs pay dividends?
Prophase Labs pays a Notavailable dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Prophase Labs dividends here
What is Prophase Labs’s EPS estimate?
Prophase Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prophase Labs have?
Prophase Labs has 41,541,206 shares outstanding.
What happened to Prophase Labs’s price movement after its last earnings report?
Prophase Labs reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of Prophase Labs?
Currently, no hedge funds are holding shares in PRPH
Company Description
Prophase Labs
Prophase Labs (PRPH) is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions for various medical conditions. The company operates primarily in the healthcare sector, with a strong emphasis on diagnostics and treatments for infectious diseases, particularly in the fields of respiratory and viral infections. Prophase Labs is known for its proprietary technologies and products that aim to improve patient outcomes and enhance the efficiency of healthcare delivery.
PRPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
ProPhase Labs is navigating through financial challenges by implementing cost reductions and restructuring efforts. The company is focused on upcoming liquidity events, including the potential sale of Nebula Genomics and significant collections from Crown Medical, which are expected to improve its financial position. However, the shortfall in COVID testing revenue and challenges in maintaining NASDAQ compliance present ongoing risks.View all PRPH earnings summariesPRPH Stock 12 Month Forecast
Average Price Target
$0.50
▲(42.86% Upside)
Technical Analysis
Ownership Overview
0.66%
Insiders
1.58% Mutual Funds
2.59% Other Institutional Investors
94.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---